Stockreport

Entrada Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]

Entrada Therapeutics, Inc.  (TRDA) 
PDF -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 -- -- Filed for regulatory authorization [Read more]